Abstract
(Englisch)
|
The MELISSA project aims to provide a clinically validated, effective, trustworthy, and cost-efficient artificial intelligence (AI)-based digital diabetes
management solution to support both health care providers (HCPs) and insulin-treated patients with diabetes (PwD) in their daily routine with
personalised treatment and care recommendations. The solution is independent of the used glucose monitoring devices and is based on the
combined use of already prototyped advanced AI-approaches and innovative tools for quantification of lifestyle and behavioural factors, taking into
consideration sex/gender aspects, age, and socio-economic parameters related to the development of diabetes. More specifically, core element of
the project is the daily insulin treatment adjustment to ensure glucose control using an already introduced self-learning approach based on
reinforcement learning. The approach is data-driven, real-time and of low computational cost and allows daily adjustment of the insulin infusion
profile, on the basis of the fluctuations in the patient?s glucose. The approach takes into consideration patients? treatment-related (glucose,
insulin, and carbohydrate intake) and conceptual information and during the project will be further extended and optimized to include additional
lifestyle and behavioural parameters. Furthermore, tools for assessing the risk of short- and long-term complications will assist HCPs in reaching
better decisions on adjustments to the treatment schemes. To meet the objectives the consortium brings together partners active in the fields of
diabetes (PwD and HCPs), diabetes technology, AI, behavioral sciences, ethics in AI, regulatory affairs, healthcare economics and clinical trials to
further co-create, clinically develop, optimize, and clinically validate an AI-based solution for more effective and cost-efficient diabetes
management through personalised treatment and care.
|
